CAMZYOS - (2.5MG, 5MG, 10MG, 15MG ; Capsule)

Generic Name	MAVACAMTEN	Innovator	BRISTOL MYERS SQUIBB
Dosage	2.5MG, 5MG, 10MG, 15MG ; Capsule	Branded US Sales	More Than $1000 mn
Probable FTF	More Than 5	Known Para IV Filers	More Than 5
Other ANDA developers	Less Than 5	Tentative Approvals	None
Final Approvals	None	Generic Launches	None
Indication	CAMZYOS is a cardiac myosin inhibitor indicated for the treatment of adults with symptomatic New York Heart Association (NYHA) class II-III obstructive hypertrophic cardiomyopathy (HCM) to improve functional capacity and symptoms.
Complexities	Yes

Executive Summary

Patent Status

Launch Timelines and Competition

Company	FTF Status / 180 days exclusivity	30-Months stay	Current Litigation Status	Current Approval Status	Likelihood of launch
*********	*** \ *********	*** **, ****	*******	****	*** ****** *** ****
****** ******	*** \ *********	*** **, ****	*******	****	*** ****** *** ****
** *****'*	*** \ *********	*** **, ****	*******	****	*** ****** *** ****

Chronology Of Events